阴道自取样本HR-HPV分型初筛联合细胞学或病毒载量二次筛查的效果
结果显示,自取样本HR-HPV阳性率13.77%,以HPV 16/18阳性直接阴道镜、非16/18阳性者细胞学(≥ASCUS)或病毒载量(≥10 RLU/CO)分流可平衡敏感度、特异度与转诊率;纳入HPV 58/31/33/52可提高敏感度。
要点
- 自取样本HR-HPV分型初筛阳性率13.77%,细胞学≥ASCUS者12.05%,病毒载量≥10 RLU/CO者8.87%。
- HPV 16/18阳性直接阴道镜,非16/18阳性者用细胞学或病毒载量分流,敏感度与特异度较高且转诊率低。
- 序贯纳入HPV 58/31/33/52阳性者直接阴道镜可提高CIN Ⅱ+、CIN Ⅲ+检出敏感度。
核心结论
- 以自取样本HR-HPV分型初筛联合细胞学或病毒载量二次筛查,可在CIN Ⅱ+、CIN Ⅲ+的敏感度、特异度及阴道镜转诊率间取得较好平衡。
- 将HPV 58、31、33、52纳入HPV 16/18阳性初筛分流并联合细胞学或病毒载量序贯二次筛查,可进一步提高筛查效率。
研究设计与样本
- 自取样本采用MALDI-TOF-MS进行HR-HPV分型,医生取样本采用HC-Ⅱ检测HR-HPV病毒载量并行液基细胞学,转诊阴道镜者均有活检组织病理结果。
主要发现
- 方案1e(任一HR-HPV阳性)检出CIN Ⅱ+、CIN Ⅲ+敏感度最高(92.70%、94.33%),但特异度(88.44%、87.58%)和PPV(18.34%、11.29%)最低,阴道镜转诊率最高(13.77%)。
- 方案1a(HPV 16/18阳性)检出CIN Ⅱ+、CIN Ⅲ+特异度最高(97.92%、97.69%),方案1d(HPV 16/18/58/31/33/52阳性)敏感度最高(88.41%、92.20%)。
- HPV 16/18阳性直接阴道镜、非16/18阳性者以细胞学≥ASCUS(方案2a)或病毒载量≥10 RLU/CO(方案3a)分流,转诊率低且CIN Ⅱ+、CIN Ⅲ+敏感度和特异度较高;在此基础上序贯增加HPV 58、31、33、52阳性者直接阴道镜可提高敏感度。
关键数值与推荐
- 方案1e检出CIN Ⅱ+、CIN Ⅲ+敏感度92.70%、94.33%,特异度88.44%、87.58%,PPV 18.34%、11.29%,阴道镜转诊率13.77%。
- 方案1a检出CIN Ⅱ+、CIN Ⅲ+特异度97.92%、97.69%;方案1d敏感度88.41%、92.20%。
- 二次筛查推荐:HPV 16/18阳性直接阴道镜,非16/18阳性者细胞学≥ASCUS或病毒载量≥10 RLU/CO分流阴道镜。
临床怎么用
- 可将阴道自取样本HR-HPV分型作为子宫颈癌初筛选项,提高筛查可及性。
- 对自取样本HR-HPV阳性者,HPV 16/18阳性建议直接阴道镜,非16/18阳性可以医生取样本细胞学(≥ASCUS)或病毒载量(≥10 RLU/CO)分流。
- 可考虑将HPV 58、31、33、52纳入分流策略以增加CIN Ⅱ+、CIN Ⅲ+检出敏感度。
局限性
- 本研究为对SHENCCAST-Ⅱ数据库的再分析,非前瞻性新研究。
- 数据来源于2009至2010年深圳单地区筛查人群,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy of high-risk HPV (HR-HPV) genotyping with vaginal self-sampling in primary screening and combining cytology or viral load for HR-HPV positive as secondary screening strategies. Methods: The data referring to HR-HPV genotyping of self-collected sample with mass array matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS), HR-HPV viral load of physician-collected sample with hybrid capture Ⅱ (HC-Ⅱ), liquid-based cytology and histology of 8 556 women were from Shenzhen cervical cancer screening trial Ⅱ (SHENCCAST-Ⅱ) conducted between April 2009 and April 2010. The data were reanalyzed to determine the sensitivity and specificity to cervical intraepithelial neoplasia (CIN) of grade 2 or worse (CIN Ⅱ+), CIN of grade 3 or worse (CIN Ⅲ+) when HR-HPV genotyping combining with colposcopy as primary screening strategy based on varied HR-HPV subtype (strategy 1, including 5 sub-strategies: 1a: HPV 16/18 positive; 1b: HPV 16/18/58 positive; 1c: HPV 16/18/58/31/33 positive; 1d: HPV 16/18/58/31/33/52 positive; 1e: any HR-HPV positive). The data were also compared to determine the efficacy of cytology (strategy 2, including 5 sub-strategies: 2a, 2b, 2c, 2d, 2e) or HR-HPV viral load (strategy 3, including 4 sub-strategies: 3a, 3b, 3c, 3d) of physician-collected sample as a triage with HR-HPV genotyping for self-sampling HR-HPV positives. Results: (1) The HR-HPV positive rate was 13.77% (1 178/8 556) in the self-collected samples of 8 556 pregnant women. Of them,the prevalences of HPV 16/18, HPV 16/18/58, HPV 16/18/58/31/33 and HPV 16/18/58/31/33/52 were 3.16% (270/8 556), 5.14% (440/8 556), 6.66% (570/8 556) and 9.81% (839/8 556), respectively. The HR-HPV viral load ≥10 relative light units/control (RLU/CO) was 8.87%(759/ 8 556), while cytological results ≥atypical squamous cell of undetermined signification (ASCUS) were 12.05% (1 031/8 556). (2) The strategy 1e had the highest sensitivities for CIN Ⅱ+, CIN Ⅲ+ which were 92.70% and 94.33%,respectively,among 14 sub-strategies,while the lowest specificity and positive predictive value (PPV). Meanwhile,the required colposcopy referral rates were much higher than other 13 sub-strategies (13.77%). The other 4 sub-strategies of strategy 1 (1a, 1b, 1c, 1d), strategy 1a had the highest specificities for CIN Ⅱ+ and CIN Ⅲ+ (97.92%, 97.69%, respectively), while 1d had the highest sensitivities for CIN Ⅱ+ and CIN Ⅲ+ (88.41%, 92.20%, respectively). (3) Both strategies of referring self-sampling HPV 16/18 positives for immediate colposcopy followed by triage physician-collected sample cytology (≥ASCUS) or viral load (≥10 RLU/CO) for non-HPV 16/18 positives had significantly higher sensitivity and specificity for CIN Ⅱ, CIN Ⅲ+, as well as lower referral rates (strategy 2a and 3a). Additionally, based on these two secondary screening strategies, cumulatively using the other four HR-HPV (HPV 58, 31, 33 and 52) positives as triage for immediate colposcopy showed an enhanced sensitivity. Conclusions: Primary HR-HPV cervical cancer screening strategy based on self-sampling with triage of cytology (≥ASCUS) or viral load (≥10 RUL/CO) provides a good balance among sensitivity, specificity for CIN Ⅱ+ and CIN Ⅲ+ and the number of tests required, referral rates. The efficacy of HR-HPV genotyping combining cytology or viral load secondary screening strategies will have a spiral escalation when HPV 58, 31, 33, 52 are included. 目的: 评价阴道自取样本高危型HPV(HR-HPV)分型检测用于子宫颈癌初筛的筛查效率,并探讨以不同HR-HPV亚型组合联合医生取样本的细胞学检查或HR-HPV病毒载量检测对自取样本HR-HPV阳性者进行二次筛查的筛查效率。 方法: 本研究的数据来自2009年4月至2010年4月深圳市子宫颈癌筛查项目Ⅱ(SHENCCAST-Ⅱ)数据库,收集其中有自取样本的基质辅助激光解吸电离-飞行时间质谱分析(MALDI-TOF-MS)技术进行的HR-HPV分型检测结果以及医生取样本的第2代杂交捕获技术(HC-Ⅱ)检测的HR-HPV病毒载量结果、子宫颈细胞学检查结果的妇女共8 556例,转诊阴道镜检查者均有活检组织病理检查结果。分析自取样本HR-HPV分型检测作为子宫颈癌初筛方案(即方案1)时,基于其不同HR-HPV亚型组合[包括5个亚方案,即1a:HPV 16和(或)18型(HPV 16/18型)阳性;1b:HPV 16/18/58型阳性;1c:HPV 16/18/58/31/33型阳性;1d:HPV 16/18/58/31/33/52型阳性;1e:所有14种HR-HPV亚型中任一亚型阳性]的阴道镜转诊方案检出子宫颈上皮内瘤变(CIN)Ⅱ及以上病变(CIN Ⅱ+)、CIN Ⅲ及以上病变(CIN Ⅲ+)的敏感度与特异度;并以自取样本HR-HPV初筛阳性者即以方案1中的各亚方案为基础,对比分析其联合医生取样本的细胞学检查(即方案2,包括2a、2b、2c、2d、2e共5个亚方案)或HR-HPV病毒载量检测(即方案3,包括3a、3b、3c、3d共4个亚方案)作为分流指标的二次筛查方案的筛查效率。 结果: (1)本研究纳入的8 556例妇女的年龄为(38.9±7.9)岁,自取样本检测的HR-HPV阳性率为13.77%(1 178/8 556),其中HPV 16/18型、HPV 16/18/58型、HPV 16/18/58/31/33型和HPV 16/18/58/31/33/52型组合的阳性率分别为3.16%(270/8 556)、5.14%(440/8 556)、6.66%(570/8 556)和9.81%(839/8 556)。医生取样本的HR-HPV病毒载量≥10相对光单位/临床阈值(RLU/CO)者占8.87%(759/8 556),细胞学结果≥未明确诊断意义的不典型鳞状上皮细胞(ASCUS)者占12.05%(1 031/8 556)。(2)方案1中,所有14种HR-HPV亚型中任一亚型阳性者(即方案1e)行阴道镜检查对检出CIN Ⅱ+、CIN Ⅲ+的敏感度在所有方案(包括3个方案共14个亚方案)中最高(分别为92.70%、94.33%),但是特异度和阳性预测值(PPV)在所有方案中最低(特异度分别为88.44%、87.58%,PPV分别为18.34%、11.29%),且阴道镜检查率在所有方案中最高(为13.77%)。方案1的其他亚方案(即方案1a、1b、1c、1d)中,检出CIN Ⅱ+、CIN Ⅲ+的特异度方案1a最高,分别为97.92%、97.69%,其他亚方案也较高,均达90%以上;但敏感度方案1d最高(分别为88.41%、92.20%)。(3)HPV 16/18型阳性者直接行阴道镜检查(即方案1a),非HPV 16/18型阳性者行医生取样本细胞学检查或HR-HPV病毒载量检测,细胞学结果达到阈值(≥ASCUS,即方案2a)或病毒载量达到阈值(≥10 RUL/CO,即方案3a)者行阴道镜检查,其阴道镜转诊率低,而筛查CIN Ⅱ+、CIN Ⅲ+的敏感度和特异度则较高。若在此两个二次筛查方案基础上,首先根据自取样本HR-HPV分型检测结果,依次增加另外4种HR-HPV亚型(即HPV 58、31、33和52型)阳性者行阴道镜检查,再以细胞学检查或病毒载量检测结果进行二次分流,筛查CIN Ⅱ+、CIN Ⅲ+的敏感度也相应提高。 结论: 以自取样本HR-HPV分型检测为子宫颈癌初筛方案,以及其联合细胞学检查或病毒载量检测进行二次筛查的方案,可以在筛查CIN Ⅱ+、CIN Ⅲ+的敏感度、特异度以及阴道镜检查率之间获得较好的平衡;将HPV 58、31、33、52型纳入HPV 16/18型阳性的初筛分流指标,并联合细胞学检查或病毒载量检测的序贯二次筛查,可进一步提高筛查效率。.
引用
- Guo CL, Luo HX, Wang C, et al. [Performance of vaginal self-sampling high-risk HPV genotyping as primary and combining cytology or viral load as secondary in cervical cancer screening]. Zhonghua Fu Chan Ke Za Zhi. 2021. PMID: 33902239. doi:10.3760/cma.j.cn112141-20200824-00357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。